Genomics Bioscience & Technology Co Ltd

Genomics Bioscience & Technology Co Ltd has a market price of 29.45 TWD and a market cap of 2,133,593,600 TWD, with a price-to-book ratio of 4.18 and a price-to-tangible-book ratio of 4.18. The company's enterprise value to EBITDA is -31.18, and its enterprise value to revenue is 3.7, indicating a high valuation relative to its earnings and revenue. The company's profitability is weak, with a return on equity of -7.73% and a return on assets of -2.76%. These metrics are below the industry norms for biotechnology and medical research firms, which typically require higher returns to justify the capital intensity and R&D investment in the sector. The company's revenue is concentrated in its domestic market, with limited geographic diversification. It operates in a single business segment focused on genetic analysis and related products, with no disclosed geographic breakdown of revenue. This concentration increases exposure to local economic and regulatory risks. The company's growth trajectory is uncertain, with a net loss of 39,427,000 TWD and a negative operating income of 84,143,000 TWD. Analysts estimate a mean revenue of 832,000,000 TWD for the next period, suggesting a potential increase from the current 708,375,000 TWD, but the company's negative cash flows and high debt-to-equity ratio of 1.23 pose challenges to sustainable growth. The company faces liquidity and dilution risks, with a current ratio of 1.2 and a negative net cash position after subtracting total debt. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative operating and free cash flows suggest potential future dilution pressures. Recent filings and transcripts indicate ongoing financial pressures, with a negative operating cash flow of -86,789,000 TWD and a free cash flow of -76,711,000 TWD. The company's capital expenditures of -84,859,000 TWD reflect ongoing investment in infrastructure, but these outflows are not yet generating positive returns.